EUVIMEDOpdag EUVIMED
Systematische ÜbersichtMetaanalyse

Efficacy, Safety and Tolerability of Lisdexamfetamine Dimesylate Treatment Compared With Placebo in Adults With Binge‐Eating Disorder: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

Maurício Prätzel Ellwanger iD, Beatriz Westphalen Pomianoski, Daniela Lopes Vieira iD, Manuela Pozza Ellwanger iD, Vírgilio Astori iD, Mateus Frizzo Messinger

European Eating Disorders Review · 2026

DOI: 10.1002/erv.70070 ↗

At a glance

Systematische Übersicht in European Eating Disorders Review, 2026. Written by Maurício Prätzel Ellwanger and 5 co-authors. Institution: Universidade do Contestado, Mafra, Santa Catarina, Brazil. Major MEDLINE topics: Lisdexamfetamine Dimesylate, Binge-Eating Disorder, Central Nervous System Stimulants. Cited 2 times so far (Crossref); 21 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Binge‐Eating Disorder (BED) causes significant psychosocial impairment and comorbidities like obesity, depression, and anxiety. Given the limited effectiveness of current treatments, Lisdexamfetamine dimesylate (LDX), approved for Attention‐Deficit/Hyperactivity Disorder‐ ADHD and BED in the U.S., may provide a promising alternative by enhancing impulse control and targeting reward pathways.

Objective

This study aims to assess the efficacy, safety, and tolerability of LDX compared with placebo in adults with BED.

Methods

We systematically searched PubMed, Embase and Cochrane databates for randomised controlled trials (RCTs). We used a random‐effects model with a 95% confidence interval (CI) to pool the data. Outcomes analysed included binge‐eating frequency, Yale‐Brown Obsessive‐Compulsive Scale for Binge‐Eating (Y‐BOCS‐BE), weight change, treatment‐emergent adverse events (TEAEs), and discontinuation rates. Sensitivity analyses were performed to assess heterogeneity. This systematic review and meta‐analysis was prospectively registered in PROSPERO (CRD42024619617).

Results

Five RCTs were included in this meta‐analysis, encompassing a total of 988 participants. LDX significantly reduced binge‐eating days per week by an average of 1.29 days and decreased obsessive‐compulsive behaviours by 6.16 points on the Y‐BOCS‐BE scale, compared with placebo. Additionally, LDX led to a significant weight reduction with an average decrease of 1.31 standardised mean differences (SMD). Diarrhoea was identified as a significant side effect not previously acknowledged in guidelines (RR = 4.06). Discontinuation rates were comparable between LDX and placebo.

Conclusion

LDX demonstrates significant efficacy in reducing binge‐eating behaviours and associated obsessive‐compulsive symptoms in patients with BED, with a tolerable safety profile. These findings support the clinical use of LDX for managing BED.

Subjects

MeSH terms (MEDLINE)

Lisdexamfetamine DimesylateBinge-Eating DisorderCentral Nervous System StimulantsHumansRandomized Controlled Trials as TopicAdultTreatment Outcome

Author keywords

adverse effectsbinge eating disorderlisdexamfetaminemeta‐analysisplacebopsychopharmacologysystematic review

Substances

Lisdexamfetamine DimesylateCentral Nervous System Stimulants

Authors and institutions

  • Universidade do Contestado, Mafra, Santa Catarina, Brazil.
  • Universidade Nove de Julho, São Paulo, Brazil.
  • Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
  • Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória, Vitória, Espírito Santo, Brazil.
  • Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.

ORCID profiles: Maurício Prätzel Ellwanger, Daniela Lopes Vieira, Manuela Pozza Ellwanger, Vírgilio Astori

Cite

APA

Ellwanger, M. P., Pomianoski, B. W., Vieira, D. L., Ellwanger, M. P., Astori, V., & Messinger, M. F. (2026). Efficacy, Safety and Tolerability of Lisdexamfetamine Dimesylate Treatment Compared With Placebo in Adults With Binge‐Eating Disorder: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials. European Eating Disorders Review. https://doi.org/10.1002/erv.70070

Vancouver

Ellwanger MP, Pomianoski BW, Vieira DL, Ellwanger MP, Astori V, Messinger MF. Efficacy, Safety and Tolerability of Lisdexamfetamine Dimesylate Treatment Compared With Placebo in Adults With Binge‐Eating Disorder: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials. European Eating Disorders Review. 2026. doi:10.1002/erv.70070

BibTeX
@article{Ellwanger2026,
  author = {Ellwanger, Maurício Prätzel and Pomianoski, Beatriz Westphalen and Vieira, Daniela Lopes and Ellwanger, Manuela Pozza and Astori, Vírgilio and Messinger, Mateus Frizzo},
  title = {Efficacy, Safety and Tolerability of Lisdexamfetamine Dimesylate Treatment Compared With Placebo in Adults With Binge‐Eating Disorder: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials},
  journal = {European Eating Disorders Review},
  year = {2026},
  doi = {10.1002/erv.70070}
}
Start for free →